Paula Jakszyn (IDIBELL & ICO) and Dr. Jordi Vilaró (URL) team has been chosen to develop a serious game that promotes physical activity in patients with chronic pathologies.
B-ACTIVE: serious games platform to promote healthy behavior in people with cancer Read More »
IDIBELL, HUB and ICO have led a European study that presents an innovative tool to assess chemotherapy-induced peripheral neuropathy (CIPN). The great advantage of this system is that it incorporates the patient’s perception, an aspect that until now medical scales did not adequately take into account.
The CUPISCO study, the largest to date on cancer of unknown primary, reveals that molecularly guided therapy is more effective than standard chemotherapy in cancer cases with an unfavorable prognosis.
Researchers from IDIBELL, CIC bioGUNE, CIBEREHD and IRB Barcelona demonstrate that iron accumulation is an important factor in the progression of liver fibrosis and cellular senescence. The study suggests that the administration of iron chelators could be an effective strategy to slow down or prevent liver fibrosis.
Dr Albert Antolin from IDIBELL and ICO highlights the relevance of multidisciplinarity and teamwork for the advance of chemical biology research, a field that is opening new paths in drug discovery and precision medicine.
Advances in chemical biology are fueled by multidisciplinarity and teamwork Read More »
Arenas was a member of the IDIBELL Scientific Advisory Board.
Neuroscientist Ernest Arenas passes away Read More »
Dr. Molina has received one of the ERS Mid-Career Gold Medals Award, which recognizes both an already consolidated outstanding research career and the work potential still ahead of a respiratory diseases specialist.
A research group from IDIBELL just published in JAMA Network Open the first article linking these two phenomena: based on a complete statistical analysis, scientists have found that on those days when air pollution increases the most, more antibiotics are prescribed.
For the first time, scientists link air pollution to the use of antibiotics Read More »
The tool, developed by IDIBELL, ICO and CIBERONC researchers, facilitates a more precise and uniform genetic variants classification, a key to making clinical decisions in patients with suspected cancer and to improving attention to patients and their families
Published in the New England Journal of Medicine, this trial has confirmed the benefits of a drug, finerenone, in an important segment of heart failure cases. The study included more than 6,000 patients from 50 countries and, in Spain it has been coordinated by IDIBELL and Bellvitge Hospital.
Bellvitge co-leads an international trial that can change the treatment of heart failure Read More »
